One year follow-up after endobronchial valve treatment in patients with emphysema without interlobar collateral ventilation

Abstract

Background One-way endobronchial valve (EBV) treatment is effective at 6 months after treatment in patients with severe emphysema and a confirmed absence of interlobar collateral ventilation. 1 Objective In this study, we investigated the efficacy of EBV treatment at 1 year follow-up. Methods Patients treated with EBV in the Stelvio trial 1 were invited for a voluntary visit 1 year after treatment. Outcomes were changes from baseline to 1 year in FEV 1 , residual volume (RV), 6-minute walk distance (6MWD) and the St. George9s Respiratory Questionnaire (SGRQ). Results Sixty-four patients received EBV treatment. At 1 year, 40 patients (26 female), mean age 59±8 years, FEV 1 0.86±0.29L, RV 4.56±1.00L, 6MWD 367±78m and SGRQ score 56±13 visited the hospital. Significant improvements (P 1 +17% (95% CI 11 to 24), RV -687ml (-918 to -456), 6MWD +61m (42 to 80), and SGRQ score -11 points (−17 to −6) For responder rates see figure. Two patients died which were deemed not to be related to the treatment. Between 6 and 12 months after treatment no pneumothoraces occurred. Conclusion EBV treatment resulted in statistically significant and clinical relevant improvements in lung function, exercise capacity and quality of life at 1 year after treatment. 1 Klooster K et al. Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. N Engl J Med 2015;373:2325-35.